Cirrhosis Liver Articles & Analysis
15 news found
HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About ...
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with dramatic and durable improvements in ...
HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About ...
(Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new data from a follow-up analysis of a subset of participants from the pivotal Phase 3 study (PROTECT) of the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, were presented in an oral presentation at The International ...
HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About PreHevbri ...
Fluid overload is a frequent complication of many large diseases – including advanced liver disease driven by NASH (non-alcoholic steatohepatitis)-related cirrhosis and heart failure – with diuretic resistance being widespread. ...
(Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting long-term durability of immune response data following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine has been accepted for oral presentation at The International Liver ...
About the POSEIDON study POSEIDON is a single-arm, open-label and within subject cross-over study of the alfapump in patients with recurrent or refractory ascites due to liver cirrhosis and is being conducted in approximately 20 centres across the U.S. and Canada. ...
In addition, Nature Scientific Reports published the company’s research analyzing gene expression at various stages of nonalcoholic fatty liver disease. NASH, one of the leading causes of transplantation, is a serious, chronic liver disease that is estimated to impact over 16 million people in the United States alone. NASH is characterized by inflammation ...
The data were presented in a poster at The Liver Meeting® 2021, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). “In people with AATLD, misfolded AAT aggregates in the liver and causes liver injury that may progress to liver fibrosis, cirrhosis ...
Breakthrough imaging solution for liver health offers physicians an accurate, accessible and affordable way to manage emerging health crisis In recognition of Liver Awareness Month this October, Sonic Incytes Medical Corp. is pleased to showcase VelacurTM, the first handheld 3D liver health assessment solution, at the American College of ...
Few important matters regarding liver transplantation treatment: It treats only the advanced stage of liver cirrhosis. ...
If left untreated, both infections can lead to cirrhosis of the liver, liver cancer, and death. Timely diagnosis is the key to controlling these diseases and stemming new infections. ...
If left untreated, both infections can lead to cirrhosis of the liver, liver cancer, and death. Timely diagnosis is the key to controlling these diseases and stemming new infections. ...
Hepatitis C (HCV) infection is the most common cause of liver cell carcinoma and liver transplants in Europe, which are possible late–stage effects of a chronic infection, alongside cirrhosis of the liver. ...